Omics · study · 2026
Heterozygous BRCA1 SNPs in the DNA Binding Domain Enhance Sensitivity to PARP Inhibition in Breast Cancer Cells
Listed in NCBI GEO
Poly(ADP-ribose) polymerase (PARP) inhibitors show efficacy in breast cancer patients with BRCA1/2 mutations.
Description
However, certain BRCA1 single nucleotide polymorphisms (SNPs) may alter protein function without complete loss of activity. This study investigates whether specific BRCA1 SNPs within the DNA binding domain affect cellular sensitivity to PARP inhibition.
We used breast cancer cell lines with heterozygous BRCA1 SNPs (CAMA-1: rs799917, rs16941, rs16942, rs1799966) or wild-type BRCA1 (T47D). Cell viability was assessed following olaparib treatment using MTT assay. Transcriptome sequencing and functional enrichment analyses were performed.
Read the rest (2 more)
CAMA-1 cells exhibited significantly enhanced olaparib sensitivity compared to T47D cells, with viability reduced to 45% versus 75% at 50 μM after 72 hours (p<0.001). Transcriptome analysis revealed 6,978 differentially expressed genes, with enrichment in DNA binding, transcriptional regulation, and cellular degradation pathways, suggesting conditional haploinsufficiency under PARP inhibition stress. Heterozygous BRCA1 SNPs in the DNA binding domain confer increased PARP inhibitor sensitivity without pathogenic mutations.
This suggests potential expansion of PARP inhibitor therapy to patients with specific BRCA1 polymorphisms, representing a novel biomarker for personalized breast cancer treatment.
Links
Get the data
- GEO FTP directory ftp.ncbi.nlm.nih.gov/geo/series/GSE315nnn/GSE315381 ↗
download · from NCBI GEO
Where it is published
- GEO accession page ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315381 ↗
landing page · from NCBI GEO
Documentation and papers
- PRJNA1396624 ncbi.nlm.nih.gov/bioproject/PRJNA1396624 ↗
project · from NCBI GEO
Topics
- Stated by source
- Expression profiling by high throughput sequencing · Homo sapiens
- From keywords
- Life Sciences
- Inferred from text
- Cancer 75% · RNA sequencing 65% · Sequencing 75%
Provenance · 1 source records, 10 field assertions
| Source | Key | Last seen | Raw |
|---|---|---|---|
| NCBI GEO | GSE315381 | 12 d ago | JSON v1 |
| Field | Assertion | Extractor | Evidence |
|---|---|---|---|
| access_level | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[disease].local:disease:cancer | enrichment · NCBI GEO | keyword-concept-rules@1.0.0 | title+description (75%) |
| concepts[field].local:field:life-sciences | mapping · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencing | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /gdstype |
| concepts[modality].local:modality:rna-seq | enrichment · NCBI GEO | keyword-concept-rules@1.0.0 | title+description (65%) |
| concepts[modality].local:modality:sequencing | enrichment · NCBI GEO | keyword-concept-rules@1.0.0 | title+description (75%) |
| concepts[organism].NCBITaxon:9606 | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /taxon |
| description | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /summary |
| publication_date | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| title | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /title |